Digital Health

Princeton – October 14, 2026 -- EDDA Technology has been named to TIME's 2026 list of the World's Top HealthTech Companies for the second consecutive year, the surgical imaging and AI company announced.

Statista partnership ranks companies on three pillars

TIME developed the list with data and rankings provider Statista. The analysis targets health technology companies that use digital technologies to make healthcare more effective and accessible. Companies were evaluated on Financial Performance, Reputation Analysis and Online Engagement.

IQQA platform has supported more than 130,000 cases

EDDA's IQQA® platform delivers 3D analysis of CT and MR images for personalized surgical and interventional planning. It has been used in more than 130,000 cases worldwide. The platform supports transplantation, resection, interventional procedures and postoperative assessment through quantitative analysis and visualization.

Sheridan – October 14, 2026 -- The global sensor patch market is valued at USD 7.9 billion in 2026 and is projected to reach USD 28.9 billion by 2031, a CAGR of 29.6%, according to a study by Wissen Research.

Chronic disease burden drives demand for remote monitoring

Sensor patches are adhesive, skin-worn devices that measure signals such as glucose, cardiac activity, and temperature and transmit the data wirelessly to a smartphone, cloud platform, or clinician. The World Health Organization links chronic disease to about 41 million deaths a year, roughly 71% of all deaths worldwide. The International Diabetes Federation estimates that about 589 million adults aged 20-79 had diabetes in 2024.

As care shifts to remote and home settings, continuous glucose monitoring (CGM) and ambulatory cardiac patches are becoming core tools for managing long-term conditions outside the clinic.

New York – September 30, 2026 -- Direct-to-patient healthcare company Ro presented the first real-world evidence on Novo Nordisk's oral Wegovy pill at the EASD2026 meeting in Milan on September 30, based on outcomes from patients on its platform who switched from an injectable GLP-1.

Ro's platform generates first clinical data on Wegovy pill switch patients

The short oral session study, co-authored by Ro clinical advisors Dr. Beverly Tchang and Dr. Louis Aronne, tracked patients with overweight or obesity who transitioned from an injectable GLP-1 and remained persistent with the Wegovy pill for three months on Ro's platform.

Durham, N.C. – September 19, 2026 -- MSK ACCESS, the musculoskeletal care program powered by RevelAi Health, has been listed in the CMS ACCESS Participant Directory on Medicare.gov, opening enrollment to Medicare beneficiaries nationwide through MSKACCESS.com.

RevelAi Health has enrolled patients in the MSK track since July 2026

The program operates under CMS's Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) Model, a voluntary Innovation Center initiative that pays participating organizations for improving outcomes among Original Medicare beneficiaries. Its musculoskeletal track targets chronic joint, bone, muscle and low back pain lasting more than three months, delivering coordinated support over a twelve-month care period. Beneficiaries can join directly or via clinician referral.

Boston – September 17, 2026 -- Outcomes4Me Inc. has appointed Jim Longley, formerly Senior Vice President of AI Partnerships at OpenEvidence, as its new Chief Revenue Officer to lead commercial expansion across pharma, provider, and diagnostic partnerships.

Longley brings two decades of health tech revenue scaling to the role

Before OpenEvidence, Longley spent nearly five years at GoodRx, rising to Senior Vice President and Head of Commercial, and prior to that spent over six years at Doximity as Vice President for Business Development and Product Innovation. Outcomes4Me CEO Maya R. Said, Sc.D., said Longley has a track record of scaling health tech companies to hundreds of millions of dollars in revenue.